SGPTH Life Science AB has secured three patents aimed at diagnosing early-stage osteoarthritis and its progression .

These patents leverage cartilage-driven neo-epitope of Cartilage Oligomeric Matrix Protein (COMP156) and (COMP644) and bone-driven neo-epitope of biglycan (BGN262) biomarkers.​

 

Artroa AB has secured and founded a patent for treating osteoarthritis with a combination of three pharmaceutical drugs with disease modifying properties.

​

The four patents can be used together and serve as a Companion diagnostics:

• Diagnosing  patients/horses with early biochemical osteoarthritis

• Identify patients/horses who are likely to benefit from a particular treatment.

• Identify patients/horses likely to be at increased risk for serious side effects as a result of treatment with a particular treatment.

• Monitor response to treatment for the purpose of adjusting treatment to achieve improved safety or effectiveness.

 

The four published patent families are:

• COMP peptide (COMP156 in diagnosing  osteoarthritis), WO2017/216289

• COMP peptide (COMP644 in diagnosing osteoarthritis) SE 2430441-2

• Combination treatment of osteoarthritis WO2020/084113

• Biglycan Peptide (BGN262 in diagnosing bonedestruction)) WO2022/26894